^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:OncoPlus
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
University of ChicagoType:
Laboratory Developed Test
over3years
[VIRTUAL] Concordance of Tissue and Cell - Free DNA - Based Next - Generation Sequencing in Patients With Lung Adenocarcinoma (IASLC-WCLC 2021)
Conclusion In this single-center, retrospective study, we demonstrate that while the rate of concordance at initial diagnosis was approximately 75%, the rate of discordance in the tests exceeds 50% at progression. On the basis of these data, we recommend both tissue and liquid biopsies at time of diagnosis and disease progression.
Clinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RB1 (RB Transcriptional Corepressor 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • EGFR exon 19 deletion • EGFR T790M • MET mutation • KRAS G12
|
FoundationOne® CDx • Guardant360® CDx • OncoPlus
Share
